397 related articles for article (PubMed ID: 9060958)
1. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA.
Dixit M; Yang JL; Poirier MC; Price JO; Andrews PA; Arteaga CL
J Natl Cancer Inst; 1997 Mar; 89(5):365-73. PubMed ID: 9060958
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein.
Arteaga CL; Hurd SD; Dugger TC; Winnier AR; Robertson JB
Cancer Res; 1994 Sep; 54(17):4703-9. PubMed ID: 8062268
[TBL] [Abstract][Full Text] [Related]
3. Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum.
Wagner M; Cao T; Lopez ME; Hope C; van Nostrand K; Kobrin MS; Fan HU; Büchler MW; Korc M
Int J Cancer; 1996 Dec; 68(6):782-7. PubMed ID: 8980184
[TBL] [Abstract][Full Text] [Related]
4. Antisense imaging of epidermal growth factor-induced p21(WAF-1/CIP-1) gene expression in MDA-MB-468 human breast cancer xenografts.
Wang J; Chen P; Mrkobrada M; Hu M; Vallis KA; Reilly RM
Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1273-80. PubMed ID: 12640557
[TBL] [Abstract][Full Text] [Related]
5. Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy.
Ohmori T; Yang JL; Price JO; Arteaga CL
Exp Cell Res; 1998 Dec; 245(2):350-9. PubMed ID: 9851876
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Li L; Keating MJ; Plunkett W; Yang LY
Mol Pharmacol; 1997 Nov; 52(5):798-806. PubMed ID: 9351970
[TBL] [Abstract][Full Text] [Related]
7. Increased cell surface EGF receptor expression during the butyrate-induced differentiation of human HCT-116 colon tumor cell clones.
Nathan DF; Burkhart SR; Morin MJ
Exp Cell Res; 1990 Sep; 190(1):76-84. PubMed ID: 1974861
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells.
Uckun FM; Narla RK; Jun X; Zeren T; Venkatachalam T; Waddick KG; Rostostev A; Myers DE
Clin Cancer Res; 1998 Apr; 4(4):901-12. PubMed ID: 9563884
[TBL] [Abstract][Full Text] [Related]
9. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
[TBL] [Abstract][Full Text] [Related]
10. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
11. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns.
Wosikowski K; Schuurhuis D; Johnson K; Paull KD; Myers TG; Weinstein JN; Bates SE
J Natl Cancer Inst; 1997 Oct; 89(20):1505-15. PubMed ID: 9337347
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
[TBL] [Abstract][Full Text] [Related]
14. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
Michaelis M; Bliss J; Arnold SC; Hinsch N; Rothweiler F; Deubzer HE; Witt O; Langer K; Doerr HW; Wels WS; Cinatl J
Clin Cancer Res; 2008 Oct; 14(20):6531-7. PubMed ID: 18927293
[TBL] [Abstract][Full Text] [Related]
16. EGF-R antisense RNA blocks expression of the epidermal growth factor receptor and suppresses the transforming phenotype of a human carcinoma cell line.
Moroni MC; Willingham MC; Beguinot L
J Biol Chem; 1992 Feb; 267(4):2714-22. PubMed ID: 1733967
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
[TBL] [Abstract][Full Text] [Related]
18. Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor.
Dickstein BM; Wosikowski K; Bates SE
Mol Cell Endocrinol; 1995 Apr; 110(1-2):205-11. PubMed ID: 7672450
[TBL] [Abstract][Full Text] [Related]
19. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
